Amarin's REDUCE-IT Analysis Suggests Risk-Weighted ApoB Improves Residual CV Risk Identification
Event summary
- Amarin presented new REDUCE-IT analysis at EAS Congress 2026, showing risk-weighted apoB (RW-apoB) better identifies residual CV risk in statin-treated patients with hypertriglyceridemia.
- RW-apoB levels were 30% higher than measured apoB, suggesting underrecognition of lipid-associated residual risk.
- RW-apoB demonstrated superior risk prediction compared to LDL-C, non-HDL-C, and apoB.
- ESC-defined intervention thresholds identified more patients at elevated risk using RW-apoB than apoB alone.
- Findings support the evolving role of icosapent ethyl (IPE) in lipid management, reinforced by recent guideline updates.
The big picture
Amarin's analysis highlights the persistent challenge of residual CV risk in statin-treated patients, particularly those with elevated triglycerides. The findings underscore the potential of RW-apoB to refine risk assessment, aligning with broader industry trends toward precision medicine in cardiovascular care. The strategic significance lies in Amarin's ability to differentiate its IPE product line in a competitive lipid management market, supported by evolving clinical guidelines.
What we're watching
- Clinical Adoption
- How quickly RW-apoB is integrated into routine clinical practice for risk stratification.
- Regulatory Impact
- Whether the findings influence future guideline updates for lipid management.
- Commercial Strategy
- The pace at which Amarin leverages these insights to expand VASCEPA/VAZKEPA's market reach.
Related topics